Northwest Biotherapeutics (NWBO) FCF Margin Growth (3y) (2013 - 2026)
Northwest Biotherapeutics (NWBO) FCF Margin Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,801.52 Bn | 66,801.23 Bn | - | - |
| 2 | Nanobiotix | 1,930.72 Bn | 1,930.66 Bn | - | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | - |
| 4 | BeOne Medicines | 471.36 Bn | 466.57 Bn | 1.35 Bn | 15,064.00 |
| 5 | Vertex Pharmaceuticals | 123.47 Bn | 116.22 Bn | 2.59 Bn | 723.00 |
| 6 | Regeneron Pharmaceuticals | 70.28 Bn | 61.52 Bn | 3.31 Bn | -1,409.00 |
| 7 | Belite Bio | 62.00 Bn | 62.00 Bn | - | - |
| 8 | Argenx Se | 56.08 Bn | 50.89 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.47 Bn | 34.46 Bn | 959.66 Mn | 6,066.00 |
| 10 | Northwest Biotherapeutics | 272.43 Mn | 270.65 Mn | - | -112,966.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -112,966.00 |
| Dec 31, 2025 | -48,764.00 |
| Sep 30, 2025 | 91,075.00 |
| Jun 30, 2025 | -214,055.00 |
| Mar 31, 2025 | 69,574.00 |
| Sep 30, 2024 | 41,711.00 |
| Jun 30, 2024 | -128,309.00 |
| Mar 31, 2024 | 120,109.00 |
| Dec 31, 2023 | -126,754.00 |
| Sep 30, 2023 | 121,589.00 |
| Jun 30, 2023 | 37.23 Mn |
| Mar 31, 2023 | -9,513.00 |
| Dec 31, 2022 | -116,490.00 |
| Sep 30, 2022 | -686,668.00 |
| Jun 30, 2022 | -149,238.00 |
| Mar 31, 2022 | -35,561.00 |
| Sep 30, 2021 | -187,787.00 |
| Jun 30, 2021 | 216,620.00 |
| Mar 31, 2021 | -202,704.00 |
| Dec 31, 2020 | 4.36 Mn |